| Literature DB >> 35241915 |
Abstract
The prevalence of nosocomial infections (NIs) is associated with different bacteria found in hospitals. These infections in their extreme conditions result in morbidity and mortality. This study aims to provide a detailed review of literary studies to identify the prevalence of nosocomial infections and antibiotic-resistance specifically in Middle Eastern countries. A literature review approach is followed in this study. It further identifies different causes and effects associated with nosocomial infections in the given regions. Relevant studies were used to extract important information, specifically related to the Middle Eastern countries. The findings indicated that nosocomial infections following antibiotic resistance are an emerging problem in Middle Eastern countries, leading to significant morbidity and mortality. Most frequently reported NIs in Middle East in our review are bloodstream infections (BSIs) (50%) and surgical site infections (SSIs) (50%) followed by urinary tract infections (UTIs). Escherichia coli and Klebsiella species among gram-negative bacteria, Staphylococcus aureus among gram-positive bacterial and fungal pathogens such as Candida species are most reported pathogens involved in nosocomial infections and resistance to penicillins, cephalosporins, carbapenems and fluoroquinolones antibiotics were significantly reported. However, most studies showed minimum resistance of pathogens against drug colistin. To control the growth rate of the given condition, government officials are suggested to ensure that hospitals follow adequate healthcare mechanisms. Also, sufficient education must be provided to the hospital staff about the causes and effects of the given disease.Entities:
Keywords: Middle East; antibiotic-resistant threat; nosocomial infection
Year: 2022 PMID: 35241915 PMCID: PMC8887909 DOI: 10.2147/IDR.S351755
Source DB: PubMed Journal: Infect Drug Resist ISSN: 1178-6973 Impact factor: 4.003
Summary of Studies Reported in the Middle East Reporting Types of Nosocomial Infections and Resistance to Antibiotic Patterns
| Author | Year | City /Country | Sample Size | Type of NI | Pathogen Resistant to Antibiotics | Resistant and Susceptible Antibiotics | Major Findings |
|---|---|---|---|---|---|---|---|
| Nasiri et al | 2019 | Tehran, Iran | 11,164 | BSI, UTI, SSI, LRI | 1) | 1) co-trimoxazole, gentamicin, ciprofloxacin and ceftriaxone. 2) ampicillin/ sulbactam (87%) | Overall NI cases 369 (3.3%), (14.2%) |
| Al Samawi et al | 2016 | Qatar | 372 | Community-acquired or hospital-acquired | Cefotaxime showed maximum resistance (147, 58.3%), colistin showed minimum resistance (2, 1.4%) | Most susceptible site for NIs was respiratory tract (117, 48.9%), NIs frequency was highest in medical ICU (66, 28.6%) | |
| Piso et al | 2017 | Syrian, Afghan, or Eritrean refugees | 261 | MRSA, ESBL, carbapenemase-producing Enterobacteriaceae | Clindamycin susceptibility (100%); erythromycin (97.4%); quinolones (92.3%); TMP/SMP (82%); fusidic acid (46.2%); tetracycline (25.6%), rifampin (100%) | MRSA colonization was 15.7%, ESBL colonization was 23.7%; no carbapenemase producers detected | |
| Esfahani et al | 2017 | Isfahan, Iran | 1077 | Respiratory system, urinary system, and blood | Ampicillin, oxacillin, co-trimoxazole, and nitrofurantoin were most resistant | Highest prevalence was found of | |
| Iyer et al | 2014 | Jeddah, Saudi Arabia | Methicillin resistant | MRSA contains SCCmec as genetic material; SCCmec contains mecA gene that is known for its ability to provide resistance against beta-lactam antibiotics | |||
| Al-Awaysheh | 2018 | Jordan | 102 | Surgical site infections (SSIs) | Highest resistance for ampicillin, minimum for vancomycin, teicoplanin and linezolid in gram-positive bacteria For gram-negative bacteria, resistance was maximum for co-amoxiclav, ciprofloxacin and ampicillin; it was minimum for meropenem, gentamicin and piperacillin-tazobactam | Overall NIs prevalence was 5.4%, | |
| Rosenthal et al | 2020 | Multicenter | 149,609 | PVCR-BSI | 1) | 1) Fluoroquinolones resistance (26.93%), amikacin (25.00%), imipenem (IPM) or meropenem (MEM) (25.93%) 2) IPM or MEM (63.15%) 3) Ceftriaxone or ceftazidime (75.00%), IPM or MEM or ertapenem (40.35%) | Overall gram-negative bacteria prevalence was 58%; |
| Al Rahmani et al | 2019 | Oman | 15,733 | BSI, surgical, urine, SCF | Gram positive bacteria’s, Gram negative bacteria, | No resistance to Colistin and tigecycline Resistance to meropenem and ciprofloxacin | 67.76% gram-positive species including (27.3%) MSSA, (25.36%) |
| Nouri et al | 2020 | Iran | 1194 | CSF, urine, tracheal aspiration | 1) | 1) Cefotetan (58.2%) 2) Ceftazidime (73.1%) |
Abbreviations: MSSA, Methicillin-sensitive Staphylococcus aureus; CoNS, Staphylococcus, coagulase negative; MRSA, Methicillin-resistant Staphylococcus aureus; ESBL, Extended Spectrum Beta-Lactamase producers; IPM, Imipenem; MEM, Meropenem; CSF, Cerebrospinal fluid; BSI, Bloodstream infection; PVCR-BSI, Peripheral venous catheter–related bloodstream infection; LRI, Lower respiratory infection; UTI, Urinary tract infection; SSIs, Surgical site infections.